Pharmacogenomic information in drug labels: European Medicines Agency perspective

Pharmacogenomics Journal

Volumn 15, Issue 3, 2015, Pages 201-210

  Ehmann, F ^a   Caneva, L ^a   Prasad, K ^a,b   Paulmichl, M ^a,c   Maliepaard, M ^a,d,e   Llerena, A ^a,f   Ingelman Sundberg, M ^g   Papaluca Amati, M ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d MEDICINES EVALUATION BOARD   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF EXTREMADURA   (Spain)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CLOPIDOGREL; IVACAFTOR; PANITUMUMAB; DRUG;

ANTINEOPLASTIC ACTIVITY; DRUG APPROVAL; DRUG INFORMATION; DRUG LABELING; DRUG METABOLISM; DRUG TRANSPORT; EUROPE; HUMAN; PHARMACODYNAMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; PHARMACOGENETICS; PROCEDURES;

DRUG LABELING; EUROPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 84929948534     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.86     Document Type: Review

References (37)

1. Vijverberg SJ, Pieters T, Cornel MC. Ethical and social issues in pharmacogenomics testing. Curr Pharm Des 2010; 16: 245-252.
2. Freuh FW. Real-world clinical effectiveness, regulatory transparency, and payer coverage: Three ingredients for translating pharmacogenomics into clinical practice. Pharmacogenomics 2010; 11: 657-660.
3. Trent RJ. Pathology practice and pharmacogenomics. Pharmacogenomics 2010; 11: 105-111.
4. ICH Topic E15 Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories http://www. ema. europa. eu/ docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002880. pdf.
5. Wilke RA, Lin DW, Roden DM, Watkins DM, Flockhart DM, Zineh I et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007; 6: 904-916.
6. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2005; 57: 119-137.
7. EMA: Guideline on the Use of Pharmacogenetic Methodologies in the Pharmacokinetic Evaluation of Medicinal Products http://www. ema. europa. eu/docs/ en-GB/document-library/Scientific-guideline/2012/02/WC500121954. pdf.
8. Maliepaard M, Nofziger C, Papaluca M, Zineh I, Uyama Y, Prasad K et al. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov 2013; 12: 103-115.
9. Concept Paper on Key Aspects for the Use of Pharmacogenomic Methodologies in the Pharmacovigilance Evaluation of Medicinal Products; (Guideline will be published January 2014) http://www. ema. europa. eu/docs/en-GB/document- library/Scientific-guideline/2012/01/WC500120775. pdf.
10. European Medicines Agency, Committee for Human Medicinal Products. Reflection Paper on Pharmacogenomic Samples, Testing and Data Handling. The Agency: London (UK), 2007 Report No. : EMEA/CHMP/PGxWP/201914/2006.
11. European Medicines Agency, Committee for Human Medicinal Products. Reflection Paper on Pharmacogenomics in Oncology (draft). The Agency: London (UK), 2008 Report No. EMEA/CHMP/PGxWP/128435/2006.
12. European Medicines Agency, Committee for Human Medicinal Products. Reflection Paper on Methodological Issues with Pharmacogenomic Biomarkers in Relation to Clinical Development and Patient Selection (Draft). The Agency: London (UK), 2011 Report No. EMA/446337/2011.
13. European Medicines Agency, Committee for Human Medicinal Products Reflection Paper on Co-development of Pharmacogenomic Biomarkers and Assays in the Context of Drug Development (Draft) London: European Medicines Agency.
14. EMA Qualification of Novel Methodologies for Medicine Development http:// www. ema. europa. eu/ema/index. jsp?curl = pages/regulation/document-listing/ document-listing-000319. jsp&mid =WC0b01ac0580022bb0.
15. Innovation Task Force (ITF) at the European Medicines Agency (EMA) http://www. ema. europa. eu/ema/index. jsp?curl = pages/regulation/general/general-content- 000334. jsp&mid = WC0b01ac05800ba1d9 Emerging Science at the EMA http:// www. ema. europa. eu/ema/index. jsp?curl = pages/special-topics/general/general- content-000339. jsp&mid = WC0b01ac05800baed8.
16. EMA Scientific Advice Procedure http://www. ema. europa. eu/ema/index. jsp?curl = pages/regulation/general/general-content-000049. jsp&mid =WC0b01ac05800229b9.
17. Pignatti F, Ehmann F, Hemmings R, Jonsson B, Nuebling M, Papaluca-Amati M et al. Cancer drug development and the evolving regulatory framework for companion diagnostics in the European Union. Clin Cancer Res 2014; 20: 1458-1468.
18. European Medicines Agency Workshop on Pharmacogenomics: from Science to Clinical Care http://www. ema. europa. eu/ema/index. jsp?curl = pages/news-and- events/events/2012/04/event-detail-000559. jsp&mid = WC0b01ac058004d5c3.
19. EC Guideline on Summary of Product Characteristics (SmPC) http://ec. europa. eu/ health/files/eudralex/vol-2/c/smpc-guideline-rev2-en. pdf.
20. European Commission "GUIDELINE ON SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)" http://ec. europa. eu/health/files/eudralex/vol-2/c/smpc-guideline- rev2-en. pdf.
21. Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF et al. Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv 2013; 6: 1111-1128.
22. Trenk D, Hochholzer W. Genetics of platelet inhibitor treatment. Br J Clin Pharmacol 2014; 77: 642-653.
23. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305: 1097-1105.
24. Ziagen SmPC http://www. ema. europa. eu/docs/en-GB/document-library/EPAR- Product-Information/human/000252/WC500050343. pdf.
25. Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D. CNA106030 Study Team. REDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat 2008; 7: 121-129.
26. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J et al. HLA-B5701 screening for hypersensitivity to Abacavir. N Engl J Med 2008; 358: 568-579.
27. Poulin-Costello M, Azoulay L, Van Cutsem E, Peeters M, Siena S, Wolf M. An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. Target Oncol 2013; 8: 127-136.
28. Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013; 31: 759-765.
29. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373: 1891-1904.
30. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009; 106: 18825-18830.
31. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, D?evínek P et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-1672.
32. Davis PB, Yasothan U, Kirkpatrick P. Ivacaftor. Nat Rev Drug Discov 2012; 11: 349-350.
33. Llerena A, Dorado P, Ramírez R, González I, Alvarez M, Peñas-Lledó EM et al. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics J 2012; 12: 176-183.
34. Work Plan Pharmacogenomics Working Party 2014-EMA http://www. ema. europa. eu/docs/en-GB/document-library/Work-programme/2010/01/ WC500069713. pdf.
35. Concept Paper on Good Genomics Biomarker Practices: http://www. ema. europa. eu/ema/doc-index. jsp?curl = pages/includes/document/document-detail. jsp?web ContentId =WC500170682&murl=menus/document-library/document-library. jsp& mid = 0b01ac058009a3dc.
36. Revision of the Medical Device Directives http://ec. europa. eu/health/medicaldevices/ documents/revision/index-en. htm.
37. Nofziger C, Papaluca M, Terzic A, Waldman S, Paulmichl M. Policies to aid the adoption of personalized medicine. Nat Rev Drug Discov 2014; 13: 159-160.